A Multicenter, Randomized, Placebo and Active Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HL231 Solution for Inhalation in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 18 Oct 2024
Price :
$35 *
At a glance
- Drugs HL 231 (Primary) ; Glycopyrrolate/indacaterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
- 09 Oct 2024 New trial record